# Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

> **NCT00006269** · PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 89 (actual)

## Conditions studied

- Colorectal Cancer
- Diarrhea

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** octreotide acetate

## Key facts

- **NCT ID:** NCT00006269
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-12
- **Primary completion:** 1999-12
- **Final completion:** —
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2012-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006269, "Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00006269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*